Antibiotic use in neonatal care: measuring cumulative exposure in point prevalence surveys identifies high infant-level antibiotic exposure P2328

Aislinn Cook and Julia Bielicki and the NeoIPC Consortium

Centre for Neonatal and Paediatric Infections, St. George's University of London



Introduction


• Infants on neonatal units may be repeatedly exposed to antibiotics

• Standard point prevalence surveys

Results




653 infants participated in at least one colonisation survey




- (PPS) cannot capture repeated treatment and may underestimate true antibiotic exposure
- Understanding patient-level antibiotic use throughout their stay is important to design and evaluate antibiotic stewardship interventions
- Cumulative (longitudinal) antibiotic measurement incorporated into PPS could provide comprehensive data on antibiotic utilization
- We aimed to investigate the added value of integrating cumulative data collection into standard PPS







229/653 infants never 422/653 infants ever received antibiotics received antibiotics Gestational age Gestational age 36 weeks (IQR: 33-38) 33 weeks (IQR: 29-38) Birthweight Birthweight: 2435 (IQR: 1801-3257) 2010 (IQR:1140-3130)




Ampicillin + Gentamicin: 350 courses

- Gentamicin: 125 courses
- Meropenem + Vancomycin: 100 courses

Vancomycin: 97 courses

Figure 1. Overall antibiotic exposure (cumulative) by antibiotic regimen and number of courses given overall. Only displaying regimens with >5 courses; colours represent WHO AWaRe groups as adapted in Russell et al (2022)¹



Methods

- The NeoIPC colonisation feasibility assessment is part of the wider NeoIPC project
- Data were collected anonymously
- 18 neonatal units in 7 European countries participated
- Colonisation surveys (4 timepoints, see below) captured antibiotic use as follows:
- Ongoing at the time of each survey (PPS)
- From admission to neonatal unit up to first survey (cumulative)
- In between each survey (cumulative)

Active/ongoing

prescription on day

antibiotic

of survey

Active/ongoing

prescription on day

antibiotic

of survey

Active/ongoing

prescription on day

antibiotic

of survey

Colonisation

Babies contribute

longitudinal data

for surveys they

Antibiotic

prevalence

at time of

survey

Active/ongoing


prescription on day


antibiotic

of survey

are on unit

surveys





~ 25% receiving active antibiotics at the time of the survey (PPS)

Survey 3 Survey 2 Survey 4 Survey 1

Figure 4. Most common antibiotic regimens received on the day of the survey (PPS) by postnatal age

The NeoIPC project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 965328



Figure 2. Antibiotic exposure (cumulative) by gestational age and WHO AWaRe categories¹

Conclusions

- 2/3 infants in high technology neonatal units in Europe are exposed to antibiotics during their stay
- The most commonly used antibiotics in this setting are from the WHO AWaRe Access group
- However, Watch and Reserve group agent use is high among the most vulnerable preterm patients and tends to occur later on during inpatient stay

Ampicillin+Gentamicin leropenem+Vancomy 6 week study period Colonisation Colonisation Survey 4 Survey 2 Antibiotic Antibiotic Antibiotic Antibiotic exposure since exposure since exposure since exposure admission to unit survey 2 since survey 3 survey 1 Colonisation Colonisation Survey 1

20

PPS largely fail to capture repeated exposures and therefore misrepresent antibiotic exposure for long-stay preterm infants in quantity & quality

• These findings are likely relevant to repeatedly exposed populations (e.g. adults in long term care facilities) and settings with multimodal distributions of length of stay

Learn more about the NeoIPC Project here! ¹ Russell, N., Stöhr, W., Plakkal, N., Cook, A., et al. (2022). Patterns of antibiotic use, pathogens and

clinical outcomes in hospitalised neonates and young infants with sepsis in the NeoOBS global neonatal sepsis observational cohort study. *MedRxiv*. https://doi.org/10.1101/2022.06.20.22276674



25% (79/315) 26% (84/318) 22% (69/307) 21% (67/317)